Sponsor or institution

Clinical trials and research at Gustave Roussy, Cancer Campus, Grand Paris

• 45Clinical trials
• 1New in 30 days
• 24Countries

Newest trials

All recruiting trials (45)

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Cohort for people with chronic myelomonocytic leukemia

  This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Amiens and 23 other locations · NCT07512882

• ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers

  This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.

  Recruiting at 6 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France and 6 other locations · NCT07483983

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Valemetostat for selected solid tumors with SWI/SNF gene alterations

  This trial will test whether valemetostat, an EZH1/2 inhibitor, can slow or stop growth in adults whose progressive solid tumors have specific SWI/SNF‑related gene changes.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 3 other locations · NCT07303387

• Short-term preoperative elacestrant alone versus elacestrant plus ovarian suppression for premenopausal early-stage ER+/HER2- breast cancer

  We will test whether 4 weeks of elacestrant alone or with ovarian suppression lowers the tumor proliferation marker Ki67 in premenopausal women with stage I–II ER+/HER2- breast cancer.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT07159451

• Tarlatamab for advanced small‑cell lung cancer and other high‑grade neuroendocrine cancers

  This study tests whether tarlatamab can help people with advanced small‑cell lung cancer or other high‑grade neuroendocrine cancers that express DLL3.

  Recruiting at 3 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Bordeaux and 2 other locations · NCT07016230

• Oral pooled fecal microbiotherapy (MaaT033) with cemiplimab to try to reverse antibiotic-related resistance in advanced NSCLC

  This trial will try whether taking an oral pooled fecal microbiotherapy (MaaT033) together with cemiplimab can restore response to immunotherapy in adults with advanced non-small cell lung cancer who became resistant after taking antibiotics.

  Recruiting at 3 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 5 other locations · NCT07001618

• Nivolumab plus cabozantinib for older adults with kidney cancer

  This trial tests the combination of nivolumab and cabozantinib in people aged 70 and older with metastatic clear-cell kidney cancer to see how it is used and tolerated in routine care.

  Recruiting Phase 4 Gustave Roussy, Cancer Campus, Grand Paris · Angers and 6 other locations · NCT06934057

• Body-fluid testing to detect early cancer in people at high risk

  This project will test whether different body-fluid tests can find early cancers in adults whose estimated 3-year risk of cancer is 4% or higher.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06907095

• Immunotherapy and local treatments for patients with oligometastatic lung cancer

  This study is testing if combining immunotherapy with local treatments can help people with a few spots of lung cancer feel better compared to standard treatments alone.

  Recruiting at 11 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Creil, Hauts-de-France and 10 other locations · NCT06840782

• Digital self-management support to improve quality of life during adjuvant hormonal therapy

  This trial tests whether a personalized mobile app plus usual care can help people with early hormone receptor–positive breast cancer have fewer endocrine therapy side effects and better quality of life.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06781996

• Testing Olaparib for Endometrial Cancer After Chemoradiation

  This study is testing if the drug Olaparib can help prevent endometrial cancer from coming back in patients with a specific genetic change after they have received standard treatment.

  Recruiting at 13 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Albi and 14 other locations · NCT06712472

• Exploring new treatments for early relapsed metastatic triple-negative breast cancer

  This study is testing new treatments for patients with early relapsed metastatic triple-negative breast cancer who haven't responded to standard chemotherapy, to see if these options can help them better.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06508216

• STEPwise program promoting ingenious online supportive solutions for cancer-related fatigue

  This trial tests three French-language digital programs to see if they reduce bothersome cancer-related fatigue in adults with cancer who report moderate to severe fatigue.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06505590

• Evaluating integrated supportive care pathways for cancer patients

  This study is testing a new supportive care program for cancer patients to see if it helps reduce their distress and improve their overall well-being over 12 weeks.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT06479057

• Combining radiation therapy with ATRA for treating oligo-metastatic solid cancers

  This study is testing whether combining a specific type of radiation therapy with a medication called ATRA can help people with certain solid cancers that have spread to a few places in the body.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Lyon and 1 other locations · NCT06439888

• Using contact X-ray brachytherapy to preserve the rectum in patients with intermediate rectal cancer

  This study is testing if adding a special type of radiation therapy to standard treatment can help people with intermediate rectal cancer keep their rectum and live longer.

  Recruiting at 11 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Avignon, France and 10 other locations · NCT06402864

• Comparing two treatment approaches for metastatic kidney cancer

  This study is testing which combination of treatments works better for people with advanced kidney cancer by comparing two different approaches using immune therapies and other medications.

  Recruiting at 33 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Vienna and 45 other locations · NCT06364631

• Using tislelizumab to treat cancer patients with detectable tumor DNA after surgery

  This study is testing if the immunotherapy drug tislelizumab can help cancer patients who have had surgery and still have traces of tumor DNA in their blood to avoid a relapse.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val De Marne · NCT06332274

• Exploring HER3-DXd treatment for advanced breast cancer

  This study is testing a new treatment called HER3-DXd, both alone and with another drug, to see if it can help people with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France · NCT06298084

• Combining preoperative radiotherapy with ASTX660 for rectal cancer treatment

  This study tests two different treatment plans for people with locally-advanced rectal cancer to see which one works better when combined with a new drug called ASTX660.

  Recruiting Phase 1 Gustave Roussy, Cancer Campus, Grand Paris · Lyon, Rhöne and 1 other locations · NCT05912075

• Creating immune organoids to study pediatric cancers

  This study is trying to create mini immune systems from kids' tissues to see how they respond to different types of pediatric cancers.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif and 1 other locations · NCT05890781

• Preventing blood clots in patients with advanced germ cell tumors undergoing chemotherapy

  This study is testing whether a blood clot prevention treatment can help people with advanced germ cell tumors who are getting chemotherapy avoid serious blood clots.

  Recruiting at 18 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Angers and 25 other locations · NCT05874063

• Validation of a treatment approach for poor-risk non-seminomatous germ cell tumors

  This study is testing a personalized treatment plan for young adults with hard-to-treat non-seminomatous germ cell tumors to see if it improves their outcomes based on how their tumor markers respond to chemotherapy.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT05705687

• New immunotherapy schedule for non-squamous lung cancer

  This study is testing if giving a lung cancer treatment called pembrolizumab every 6 weeks instead of every 3 weeks is just as effective for patients with metastatic non-squamous lung cancer while making it easier for them.

  Recruiting at 35 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Namur and 36 other locations · NCT05692999

• Molecular profiling for treating pediatric and young adult cancers

  This study is testing if using genetic information from tumors can help doctors find better treatments for kids and young adults with hard-to-treat cancers.

  Recruiting at 29 sites Gustave Roussy, Cancer Campus, Grand Paris · Amiens, France and 28 other locations · NCT05691608

• Treatment of advanced lung cancer with sotorasib for patients with a specific KRAS mutation

  This study is testing if a new drug called sotorasib can help people with advanced lung cancer who have a specific KRAS mutation and have already tried other treatments.

  Recruiting at 4 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Lyon and 4 other locations · NCT05631249

• Exploring immune responses to cell therapy in tumors

  This study is testing how the immune system reacts to a new cell therapy in patients with different types of tumors to see if these reactions can help predict how well the treatment works and what side effects might occur.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne · NCT05481502

• New treatment for Diffuse Intrinsic Pontine Glioma

  This study is testing if a new drug called ONC201 can help kids with Diffuse Intrinsic Pontine Glioma live longer without their cancer getting worse, compared to an existing treatment called everolimus.

  Recruiting at 53 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Brussels and 55 other locations · NCT05476939

• Using liquid biopsy to improve cancer treatment in community hospitals

  This study is testing if using a simple blood test can help doctors make better treatment choices for people with advanced cancer at community hospitals.

  Recruiting at 13 sites Gustave Roussy, Cancer Campus, Grand Paris · Bayonne and 20 other locations · NCT05283044

• Organoid-based precision medicine for advanced, pretreated solid cancers

  This study tests whether patient-derived tumor organoids can guide personalized treatment choices for adults with advanced, pretreated solid tumors.

  Recruiting at 9 sites Gustave Roussy, Cancer Campus, Grand Paris · Bordeaux, France and 10 other locations · NCT05267912

• Patritumab deruxtecan for unresectable or metastatic hormone-receptor–positive, HER2-negative breast cancer

  This trial will try patritumab deruxtecan (U3-1402) every three weeks in adults with HER2-negative, hormone-receptor–positive advanced or metastatic breast cancer whose disease progressed after endocrine therapy plus CDK4/6 inhibitors.

  Recruiting at 10 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 10 other locations · NCT04965766

• Molecular analysis for cancer patients at Gustave Roussy

  This study is testing a way to find specific genetic changes in cancer patients to see if they can get targeted treatments that might work better for them.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 3 other locations · NCT04932525

• Using near-infrared imaging with indocyanine green to improve surgery for head and neck cancer

  This study is testing if a special imaging technique using a dye can help doctors find and remove all the cancer during surgery for patients with head and neck cancer.

  Recruiting at 2 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Anderlecht and 1 other locations · NCT04842162

• Access to innovative cancer treatments for young patients

  This study is trying to gather information on new cancer treatments for kids and young adults who aren't responding to standard therapies to see how safe and effective they are.

  Recruiting at 32 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 31 other locations · NCT04477681

• Treatment for high-risk neuroblastoma

  This study is testing different chemotherapy and radiation treatments to see which ones work best for children with high-risk neuroblastoma.

  Recruiting at 106 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Sydney, Randwick and 141 other locations · NCT04221035

• Using low-level laser therapy to prevent mouth sores in young cancer patients

  This study is testing if low-level laser therapy can help prevent painful mouth sores in children and young adults receiving high-risk chemotherapy.

  Recruiting at 5 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 4 other locations · NCT03983369

• Using aspirin and atorvastatin for advanced prostate cancer treatment

  This study is testing if taking aspirin and atorvastatin together can help men with advanced prostate cancer live longer when they start their first treatment.

  Recruiting at 15 sites Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Olomouc and 29 other locations · NCT03819101

• Assessing neurocognitive risks in children with solid tumors

  This study is trying to see how solid tumors and their treatments affect the thinking and learning abilities of children aged 6 to 16.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val De Marne · NCT03609112

• Measuring heart calcium levels in adults treated for childhood cancer

  This study is testing if adults who had radiation therapy for childhood cancer have higher heart calcium levels compared to others, to see if the treatment affects their heart health.

  Recruiting at 3 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val De Marne and 2 other locations · NCT03604627

• Immunotherapy after surgery for head and neck cancer

  This study is testing if a new immunotherapy treatment after surgery can help people with recurring head and neck cancer live longer without the disease coming back, compared to older treatments.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val De Marne · NCT03406247

• Investigating biomarkers in ovarian cancer

  This study is trying to find specific markers in ovarian cancer patients' samples to see how they relate to treatment success and to improve personalized treatment options.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne · NCT03010124

• Therapeutic stratification for pediatric cancer patients with relapsed or refractory tumors

  This study is testing if targeted cancer treatments can help children and teens with tough-to-treat tumors by using their specific genetic information to guide the best therapy.

  Recruiting at 22 sites Phase 1/2 Gustave Roussy, Cancer Campus, Grand Paris · Copenhagen and 22 other locations · NCT02813135

• Biological samples bank for childhood cancer treatment effects

  This project collects saliva and blood from adults who were treated for cancer in childhood to see if genetic differences influence later iatrogenic risks.

  Recruiting at 3 sites Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 2 other locations · NCT02666625

Quick answers

How many clinical trials run by Gustave Roussy, Cancer Campus, Grand Paris are recruiting right now?

45, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in France (45 trials), Spain (5 trials), Belgium (4 trials), Denmark (4 trials), Italy (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 13, Phase 2: 9, Phase 1/2: 4, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →